ArticleTransplant international : official journal of the European Society for Organ Transplantation2025
Developing an Adult Living Donor Liver Transplant Program in Western Europe: The Rotterdam Experience.
Article in Transplant international : official journal of the European Society for Organ Transplantation, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
15 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Liver transplantation (LT) is curative for end stage liver disease. Expanding LT indications with limited deceased donor grafts has created organ shortages. Living donor liver transplant (LDLT) increases available organs. In 2019, we restarted our adult LDLT program. We describe our steps to create a successful LDLT program, and our outcomes. Critical steps of program development included market analysis, creation of protocols based on best care practices and a rigorous education program. Patients and donors were then actively recruited for LDLT. Outcomes were measured as morbidity (≥3 on the Clavien-Dindo grading system) and mortality. Between January 2019 and August 2024, 54 LDLT were performed. 2 (3%) donors experienced grade 3A and 7 (12%) donors experience grade 3B complications. There was no donor mortality. 22 (41%) patients were transplanted for PSC, the average MELD score was 13 (6-32). 35 (65%) patients had Roux-en-Y reconstructions. 25 (46%) complications were experienced in 22 (40%) patients, there were 2 recipient deaths. Patient and graft survival after LDLT was 97% and 97%, respectively. This paper reported the successful establishment of a LDLT program in the Netherlands. Establishing a LDLT program brings its own unique challenges, with careful planning and persistence, these challenges can be overcome.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.